Should I buy Quest Diagnostics (DGX) stock or is it too late?

Quest Diagnostics · Health Care · price $245

See the full Quest Diagnostics (DGX) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: JP Morgan — 67% of its targets hit on this sector (355 calls tested). It aims for $250 (+2.2 %), call made on July 29, 2026, maturing on July 29, 2027 (30 d ago).

The 6 reliable analysts $250+2.2 %

The 1 other firm $210-14 %

How to read it: the 6 reliable firms are not filtered by optimism — 5 aim above the price, 1 below, hence their $250 median. “The 1 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Quest Diagnostics

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Mizuho	79 %	+12.8 %	14	$260 +6%
Credit Suisse	67 %	+6.5 %	6	—
Morgan Stanley	58 %	+5.7 %	12	—
Canaccord Genuity	57 %	+4.6 %	7	—
B of A Securities	56 %	+1.1 %	9	—

In short — Should you invest in Quest Diagnostics? Is it too late, still worth it? Analysts are split (29% buy, median target $250, i.e. +2%), and the most reliable on DGX targets even higher. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

The most reliable firm on DGX, Baird (100% hit rate, 4 scored calls), targets $255 (call made on July 24, 2026, maturing on July 24, 2027) (+4%) in its most recent call, and $229 (call made on April 22, 2026, maturing on April 22, 2027) (-6%) in the one coming due soonest.
Pays a dividend (1.5% yield), raised for 14 years — regular income on top of potential upside.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 7 ratings, 5 are neutral.
Limited upside: the median target is only +2% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on DGX

Median target $250 (+2%) · 7 ratings · Hold consensus

Strong Buy00%

Buy229%

Hold571%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Quest Diagnostics now?

We won't decide for you. The facts: 29% of analysts rate it a buy, median target $250 (+2%), and Baird (most reliable on DGX, 100%) targets $255. Weigh that against valuation (P/E ~26). This is not personalized advice.

Is it too late to invest in Quest Diagnostics?

The stated upside is small: the median target ($250) sits just +2% from the price ($245) (most reliable on DGX: Baird, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Quest Diagnostics still worth investing in?

It depends on the gap between the price ($245) and its estimated value: analysts target $250 on median (+2%), with 29% buys (most reliable on DGX: Baird, 100%). Cross-check with their real reliability on DGX and the cautions above. Information, not advice.

What's the main risk in buying DGX?

The consensus is not unanimous: of 7 ratings, 5 are neutral.

→ Go deeper: the full Quest Diagnostics profile (consensus, analyst reliability, price target, performance).